On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

  • Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor
  • TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient outcomes
  • POAI to begin sales of TumorGenesis’ innovative culture media in the first half of 2020

TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of ovarian cell types while growing them in the laboratory. This breakthrough approach is likely to help POAI become a frontrunner in providing the needed tools for personalized medicine and new drug development, which carries important implications for the company’s future valuation.

For years, clinicians believed that isolating a patient’s tumor would lead to new understandings about the cancer – this has proven to be only partly true and has resulted in costly, ineffective drug diagnoses that have robbed patients of precious time. To substantially enhance the effectiveness of cancer treatment, a much more diverse picture of patient tumors is needed – one that takes into account each individual’s unique biodiversity and the unique biodiversity of each tumor. POAI’s TumorGenesis division is at the forefront of a whole new trend in cancer research that revolves around patient derived xenografts (PDx).

Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By “fooling the tumor” with an imitative environment, new drugs are able to be tested and potentially approved – all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally – revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug response profiles and artificial intelligence-driven predictive modeling capabilities.

TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo, (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.

In light of the traditional past practice of studying how cancer cell lines react to induced mutation (a practice that has since proven to be seriously flawed), cancer researchers are shifting their focus to PDx techniques, which have grown into a multibillion-dollar industry. TumorGenesis is poised to become a dominant figure in this emerging space. US Biological Corporation of Salem, Massachusetts has been selected as the distributor of TumorGenesis media and discovery kits.

Parent company POAI already presents a major leap in the cancer research industry. As of today, the company has validated and will begin sales its new PDx models for ovarian cancer (http://ibn.fm/1hsgV) in the first half of this year. The company now has 25 validated ovarian cancer cell types. This signifies remarkable comprehension of the notoriously difficult-to-detect cancer, as 15 out of the 25 cell lines account for nine out of ten ovarian cancers diagnosed worldwide. As researchers separate these types and analyze their reaction to drug samples, POAI’s findings could greatly improve future patient outcomes.

In line with its CancerQuest2020 initiative, ovarian cancer is just POAI’s first target. With monetization, the company plans to diversify and expand its catalogue of validated cancers; future plans include thyroid, breast, colon, and prostate cancers, among others.

TumorGenesis presents POAI with multiple revenue streams. Based on its unique PDx samples, the company is testing drugs individually and holistically against its massive library of ovarian cancer cell types. Using this approach, the company is building kits for cancer research laboratories worldwide. The company is also committed to immunological research. Its proprietary Ovarian Cancer Kit can help simulate a patient’s cancer environment, and these new tools can be used to help isolate various strains of the complex tumor environment that to this date, have never been isolated but seen by genetic and proteomic analysis. Once isolated, these subtypes of tumor cells can be studied, new antibodies developed and new tools researched for killing not just the fast growing tumor variants but also the entire tumor.

The latest developments in TumorGenesis’ PDx efforts could secure a significant segment of the cancer research industry. TumorGenesis’ advances in ovarian cancer models provides POAI a unique competitive advantage that could easily be converted into rapid market expansion. This expansion would not only further validate efficacy and grow market share, it would likely lead to significant increase in POAI’s market valuation. As the company continues achieving milestones of its CancerQuest2020, POAI is setting up to become one of the biotech superstars of 2020 and beyond.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

From Our Blog

Sigma Labs Inc. (NASDAQ: SGLB) Ensures Quality Assurance in 3D-Metal-Printing with Patented Software

March 31, 2020

Laser-based metal-additive manufacturing is the leading technology in the metal 3D-printing space LPBF being used in additive manufacturing at increasing rate, allowing users to quickly create prototypes, more complex geometries Sigma Labs leads industry in providing invaluable quality-control technology throughout metal AM space Laser-based metal-additive manufacturing is the leading technology in the metal 3D-printing world, […]

Rotate your device 90° to view site.